YBX1 and breast carcinoma: According to our results, YB1 CTD markedly decreased cell cycle‐promoting factor cyclin B1 levels and increased cyclin‐dependent kinase inhibitor p21 levels in SK‐BR‐3 breast cancer cells, which inhibited SK‐BR‐3 cell proliferation.